S. Rashid

发表

Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE)

S. Yusuf, Arya M. Sharma, M. Tarnopolsky, 2011, PloS one.

Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.

A. K. Agarwal, R. Hammer, A. Garg, 2009, Cell metabolism.

Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians

S. Yusuf, Sonia S Anand, J. Otvos, 2015, European journal of preventive cardiology.

PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia

J. Kastelein, S. Rashid, 2013, Expert review of cardiovascular therapy.

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

O. Palyha, A. Strack, Larissa C Wilsie, 2012, Journal of the American College of Cardiology.

Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin Signaling

S. Rashid, M. Melone, Justina Costandi, 2011, Circulation research.

Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation

G. Lewis, K. Adeli, P. Barrett, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.

P. MacDonald, M. Vranic, M. Wheeler, 1999, Diabetes.

The mechanisms of differential glucocorticoid and mineralocorticoid action in the brain and peripheral tissues.

G. Lewis, S. Rashid, 2005, Clinical biochemistry.

What do high blood resistin levels mean for patients on statin therapy?

S. Rashid, 2013, Expert review of cardiovascular therapy.

Statins and primary prevention: is all the evidence in?

G. Francis, S. Rashid, 2008, The Canadian journal of cardiology.

Effect of Obesity on High‐density Lipoprotein Metabolism

J. Genest, S. Rashid, 2007, Obesity.

HDL metabolism in hypertriglyceridemic states: an overview.

G. Lewis, B. Lamarche, S. Rashid, 1999, Clinica chimica acta; international journal of clinical chemistry.

Should cholesterol-lowering medications be available in Canada without a prescription?

S. Rashid, 2007, The Canadian journal of cardiology.

Beta-blockade, but not normoglycemia or hyperinsulinemia, markedly diminishes stress-induced hyperglycemia in diabetic dogs.

M. Vranic, G. Lewis, M. Niwa, 2000, Diabetes.

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Deanna L. Plubell, Rachel M. Devay, I. Predazzi, 2016, Cardiovascular research.

Local effects of human PCSK9 on the atherosclerotic lesion

Rachel M. Devay, I. Predazzi, M. Linton, 2016, The Journal of pathology.

On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

S. Fazio, S. Rashid, H. Tavori, 2015, Atherosclerosis.

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms

M. Linton, S. Fazio, S. Rashid, 2014, Circulation.

Response to letter regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms".

M. Linton, S. Fazio, S. Rashid, 2015, Circulation.

The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.

G. Lewis, K. Uffelman, S. Rashid, 2002, Journal of diabetes and its complications.

Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice

R. Hammer, J. McDonald, J. Horton, 2017, eLife.

Expression of Human Hepatic Lipase in the Rabbit Model Preferentially Enhances the Clearance of Triglyceride‐Enriched Versus Native High‐Density Lipoprotein Apolipoprotein A‐I

D. Rader, G. Lewis, K. Uffelman, 2003, Circulation.

Triglyceride enrichment of HDL does not alter HDL-selective cholesteryl ester clearance in rabbits.

P. Vicini, G. Lewis, K. Adeli, 2001, Journal of lipid research.

Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines Published, JLR Papers in Press, May 16, 2005. DOI 10.1194/jlr.M500038-JLR200

J. Genest, M. Marcil, M. Denis, 2005, Journal of Lipid Research.

Mechanism of HDL lowering in insulin resistant states.

G. Lewis, B. Lamarche, K. Uffelman, 2001, Advances in experimental medicine and biology.

Lower LDL is better – can this be achieved with CETP inhibition therapy?

S. Rashid, 2020, Expert review of cardiovascular therapy.

PCSK9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title: Rashid et al.; PCSK9 Promotes Intestinal ApoB Overproduction

M. Linton, S. Fazio, S. Rashid, 2014 .

The impairment of glucoregulatory responses to stress in diabetes

S. Rashid, 1997 .

PCSK 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein-B Lipoproteins Through Both LDL-Receptor Dependent and Independent Mechanisms Running title :

M. Linton, S. Fazio, S. Rashid, 2014 .

Dr. Mladen Vranic—A Legend in Diabetes Research: 1930–2019

A. Cherrington, S. Rashid, 2020, Diabetes Care.

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

R. Hammer, J. Horton, Norma N. Anderson, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity.

G. Lewis, Shirya Rashid, Takehiko Watanabe, 2003, Clinical biochemistry.

Identification of a novel human cellular HDL biosynthesis defect.

J. Genest, M. Marcil, I. Ruel, 2009, European heart journal.

Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin.

S. Rashid, 2009, World journal of cardiology.

Risk factors for early myocardial infarction in South Asians.

N. Khandaker, S. Rashid, 2007, JAMA.

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

S. Rashid, H. Tavori, M. Melone, 2014, Expert review of cardiovascular therapy.

Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit

G. Lewis, P. Barrett, K. Uffelman, 2002, Circulation.

Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? Published, JLR Papers in Press, May 9, 2006.

G. Lewis, B. Patterson, Bruce W Patterson, 2006, Journal of Lipid Research.

Mechanisms by which Elevated Resistin Levels Accelerate Atherosclerotic Cardiovascular Disease

S. Rashid, 2013 .

Author response: Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice

R. Hammer, J. McDonald, J. Horton, 2017 .

Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice

R. Hammer, J. McDonald, J. Horton, 2017, eLife.

Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin Signaling

S. Rashid, M. Melone, Justina Costandi, 2011, Circulation research.

Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.

R. Hammer, A. Garg, J. Horton, 2009, Cell metabolism.

Effect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs.

M. Vranic, R. Kawamori, A. Giacca, 2000, Metabolism: clinical and experimental.